Targets › INH
2 programs from 2 companies in 5 trials: 4 Phase 4, 1 Phase 1; Infectious disease; next expected readout Aug 2029.
Open in Phaseline: the race on INH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Affiliated Hospital of Nantong University | Isoniazid Enoyl-[acyl-carrier-protein] reductase inhibitor | INH, RIF, RPT | Phase 4 | Latent Tuberculosis Infection (LTBI) | Aug 2029 |
| The Aurum Institute NPC | Rifapentine Bacterial DNA-directed RNA polymerase inhibitor | RIPA, INH, UNKNOWN | Phase 4 | HIV Seropositivity | – |
HIV Seropositivity (3) Latent Tuberculosis Infection (LTBI) (2)
small molecule (2)
The Aurum Institute NPC (1) Affiliated Hospital of Nantong University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.